Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Nanobac Pharmaceuticals Announces Continuation of Space Act Agreement with NASA: NASA to Study Characterization of the Physical and Chemical Propertie

Abstract:
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or the "Company") is pleased to announce the signing of a Space Act Agreement with NASA's Johnson Space Center (JSC), Houston Texas, to collaborate on research on Calcifying Nanoparticles (CNP) and its nature and role in pathological calcification, including the detection and treatment of the pathogen. Since Astronauts may be more prone to an increased rate of pathological calcification while in a zero gravity environment, the collaboration will bring a new approach to NASA's need to better understand the effects of long-term space travel on humans.

Nanobac Pharmaceuticals Announces Continuation of Space Act Agreement with NASA: NASA to Study Characterization of the Physical and Chemical Propertie

TAMPA, FL | Posted on September 18th, 2007

NANOBAC and NASA are interested in pathological calcium phosphate particles found in diseases such as kidney stones, prostatitis, and arthritis, which are all conditions that accelerate in humans in a zero gravity environment. This collaboration would provide NASA the opportunity to utilize NANOBAC's diagnostic and treatment experience in this field in support of NASA's exploration goals related to understanding the effects of long-term space travel on humans and offer Nanobac the opportunity to further develop its methods and utilize NASA instrumentation to further characterize the CNPs.

Part of the instrumentation to be used is the Focused Ion Beam (FIB) in order to mill CNP samples for use in Scanning and Transmission Electron Microscopy (SEM, TEM, STEM) analyses to characterize internal CNP mineralogy. Additionally, Laser Microprobe, Organic Mass-Spectrometric analyses and Nano-SIMS elemental and isotopic analyses will be performed to characterize the organic content of the CNPs.

"We are pleased to be able to extend our Director of Science time at NASA for these important projects," commented Dr. Benedict Maniscalco, Nanobac's Co-Chair and Chief Medical Officer. "We appreciate the opportunity to work with some of the country's most talented scientists."

Nanobac's Director of Science Neva Ciftcioglu added: "The continuation of our collaborative research with NASA will give us an opportunity to stay with exceptionally experienced diverse scientific members helping us to complete the biological definition of the unique agent: calcifying nanoparticles."

####

About Nanobac Pharmaceuticals Inc.
Our objective is to develop methods to treat Calcifying Nanoparticles (CNPs), and by so doing find more effective approaches to the diseases associated with them.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

For more information, please click here

Contacts:
Nanobac Pharmaceuticals, Tampa
Brady Millican
813-264-2241
or
Redwood Consultants
Jens Dalsgaard
415-884-0348

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Aerospace/Space

Under pressure - space exploration in our time: Advancing space exploration through diverse collaborations and ethical policies February 16th, 2024

Bridging light and electrons January 12th, 2024

New tools will help study quantum chemistry aboard the International Space Station: Rochester Professor Nicholas Bigelow helped develop experiments conducted at NASA’s Cold Atom Lab to probe the fundamental nature of the world around us November 17th, 2023

Manufacturing advances bring material back in vogue January 20th, 2023

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project